Cargando…
Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody
In the era of immunotherapeutic control of cancers, many advances in biotechnology, especially in Ab engineering, have provided multiple new candidates as therapeutic immuno-oncology modalities. Bispecific Abs (BsAbs) that recognize 2 different antigens in one molecule are promising drug candidates...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Immunologists
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901699/ https://www.ncbi.nlm.nih.gov/pubmed/35291652 http://dx.doi.org/10.4110/in.2022.22.e4 |